オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - paracetamol, quantity: 10 mg/ml - injection, intravenous infusion - excipient ingredients: hydrochloric acid; cysteine hydrochloride monohydrate; dibasic sodium phosphate dihydrate; mannitol; nitrogen; water for injections; sodium hydroxide - paracetamol-aft 10mg/ml, solution for infusion is indicated for the relief of mild to moderate pain and the reduction of fever where an intravenous route of administration is considered clinically necessary.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 4.16 mg - tablet, chewable - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; mannitol; magnesium stearate; iron oxide red; aspartame; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: hyprolose; croscarmellose sodium; iron oxide red; magnesium stearate; hypromellose; iron oxide yellow; macrogol 6000; titanium dioxide; lactose monohydrate; microcrystalline cellulose - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - montelukast sodium, quantity: 5.2 mg - tablet, chewable - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; mannitol; magnesium stearate; iron oxide red; aspartame; flavour - -prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. ,-symptomatic treatment of seasonal allergic rhinitis.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sini australia pty ltd - propolis -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sini australia pty ltd - natural fish oil, quantity: 1000 mg (equivalent: docosahexaenoic acid, qty 120 mg; equivalent: eicosapentaenoic acid, qty 180 mg) - capsule, soft - excipient ingredients: d-alpha-tocopherol; purified water; soya oil; glycerol; gelatin - helps maintain/support healthy cholesterol ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support blood vessel health

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

n-hance pty ltd - epimedium sagittatum,ginkgo biloba,panax ginseng,paullinia cupana,schisandra chinensis,tribulus terrestris,zinc amino acid chelate -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

rbk nutraceuticals pty ltd - squalene, quantity: 1 g - capsule, soft - excipient ingredients: soya oil; gelatin; glycerol; d-alpha-tocopherol; purified water - antioxidant/reduce free radicals formed in the body ; maintain/support general health and wellbeing

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

integria healthcare australia pty ltd - eucalyptus fruticetorum,lavandula angustifolia,melaleuca alternifolia,pelargonium graveolens,rosmarinus officinalis,sassafras albidum -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ticarcillin sodium, quantity: 3.3 g (equivalent: ticarcillin, qty 3 g); potassium clavulanate, quantity: 119.2 g (equivalent: clavulanic acid, qty 100 mg) - injection, powder for - excipient ingredients: - timentin is indicated in the treatment of serious infections caused by susceptible strains of beta-lactamase producing organisms in the conditions listed below: septicaemia (and bacteraemia) cases caused by beta-lactamase producing organisms including strains of klebsiella pneumoniae, e.coli, staphylococcus aureus and pseudomonas aeruginosa. lower respiratory infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus, haemophilus influenzae and klebsiella pneumoniae. bone and joint infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus. skin and skin structure infections cases caused by beta-lactamase producing susceptible organisms including strains of staphylococcus aureus, klebsiella pneumoniae and e. coli. urinary tract infections cases caused by beta-lactamase producing susceptible organisms including strains of e.coli, klebsiella pneumoniae, pseudomonas aeruginosa and staphylococcus au